Sulfone derivatives reduce growth, adhesion and aspartic protease SAP2 gene expression

World Journal of Microbiology and Biotechnology

Volumn 30, Issue 9, 2014, Pages 2511-2521

  Bondaryk, Małgorzata ^a   Ochal, Zbigniew ^b   Staniszewska, Monika ^a  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Adhesion; Candida albicans; SAP2; Sulfone derivatives; Virulence

Indexed keywords

ADHESION; CELL CULTURE; GENE EXPRESSION; YEAST;

ASPARTIC PROTEASE; CANDIDA ALBICANS; EPITHELIAL TISSUE; RELATIVE QUANTIFICATION; RESISTANCE MECHANISMS; SAP2; VIRULENCE; VIRULENCE FACTORS;

CANDIDA;

CANDIDA; CANDIDA ALBICANS;

ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; FUNGAL PROTEIN; SAP2 PROTEIN, CANDIDA; SULFONE;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CACO 2 CELL LINE; CANDIDA ALBICANS; CELL ADHESION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STRUCTURE ACTIVITY RELATION; TEMPERATURE; TIME;

ANTIFUNGAL AGENTS; ASPARTIC ACID ENDOPEPTIDASES; CACO-2 CELLS; CANDIDA ALBICANS; CELL ADHESION; EPITHELIAL CELLS; FUNGAL PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TEMPERATURE; TIME FACTORS;

EID: 84905106574     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-014-1676-2     Document Type: Article

References (53)

1. Ahmad A, Kabir MA, Kravets A, Andaluz E, Larriba G, Rutschenko E (2008) Chromosome instability and unusual features of some widely used strains of Candida albicans. Yeast 25: 433-448.
2. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P, MacCallum D, Odds FC, Schäfer W, Klis F, Monod M, Hube B (2006) Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 281: 688-694.
3. Amberg DC, Burke DJ, Strathern JN (2005) Yeast RNA isolations, Techniques and Protocols #6. In: Amberg DC, Burke DJ, Strathern JN (eds) Methods in yeast genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 127.
4. Bondaryk M, Staniszewska M (2013) The in vitro expression of Candida albicansSAP1-10 genes in the intestinal candidiasis model. Poster presented at 31st annual meeting of the European society for pediatric infectious diseases (ESPID 2013), Milan, Italy, May 28-June 1, 2013. Abstract no. 896.
5. Borg-von Zepelin M (1999) HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113: 747-751.
6. Borys KM, Korzyński MD, Ochal Z (2012) A simple and efficient synthesis of trihalomethyl and dihalomethyl aryl sulfones. Tetrahedron Lett 53: 6606-6610.
7. Braga-Silva LA, Santos ALS (2011) Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr Med Chem 18: 2401-2419.
8. Braga-Silva LA, MesMesquita DG, Ribeiro MD, Carvalho SM, Fracalanzza SE, Santos AL (2009) Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases. Braz J Med Biol Res 42: 765-770.
9. Braga-Silva LA, Mogami SS, Valle RS, Silva-Neto ID, Santos AL (2010) Multiple effects of amprenavir against Candida albicans. FEMS Yeast Res 10: 221-224.
10. Cadicamo CD, Mortier J, Wolber G, Hell M, Heinrich IE, Michel D, Semlin L, Berger U, Korting HC, Höltje HD, Koksch B, Borelli C (2013) Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans. Biochem Pharmacol 85: 881-887.
11. Calugi C, Trabocchi A, De Bernardis F, Arancia S, Navarra P, Cauda R, Cassone A, Guarna A (2012) Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorg Med Chem 20: 2401-2419.
12. Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC (2007) Candida albicans drug resistance-another way to cope with stress. Microbiology 153: 3211-3217.
13. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22: 291-321.
14. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180: 448-453.
15. Chaffin WL (2008) Candida albicans cell wall proteins. Microbiol Mol Biol Rev 72: 495-544.
16. Chibana H, Uno J, Cho T, Mikami Y (2005) Mutation in IRO1 tightly linked with URA3 gene reduces virulence of Candida albicans. Microbiol Immunol 49: 937-939.
17. CLSI (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition. In: Wayne PA (ed) CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne.
18. Copping VMS, Barelle CJ, Hube B, Gow NA, Brown AJ, Odds FC (2005) Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother 55: 645-654.
19. Correia A, Lermann U, Teixeira L, Cerca F, Botelho S, da Costa RM, Sampaio P, Gärtner F, Morschhäuser J, Vilanova M, Pais C (2010) Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis. Infect Immun 78: 4839-4849.
20. De Bernardis F, Mondello F, San Milán R, Pontòn J, Cassone A (1999) Biotyping virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 37: 3481-3486.
21. García MG, O'Connor JE, García LL, Martínez SI, Herrero E, del Castillo Agudo L (2001) Isolation of a Candida albicans gene, tightly linked to URA3, coding for a putative transcription factor that suppresses a Saccharomyces cerevisiae aft1 mutation. Yeast 18: 301-311.
22. Garibotto FM, Garro AD, Masman MF, Rodríguez AM, Luiten PG, Raimondi M, Zacchino SA, Somlai C, Penke B, Enriz RD (2010) New small-size peptides possessing antifungal activity. Bioorg Med Chem 18: 158-167.
23. Gillum AM, Tsay EYH, Kirsch DR (1984) Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198: 179-182.
24. Hashash R, Younes S, Bahnan W, El Koussa J, Maalouf K, Dimassi HI, Khalaf RA (2011) Characterization of Pga1, a putative Candida albicans cell wall protein necessary for proper adhesion and biofilm formation. Mycoses 54: 491-500.
25. Hube B, Naglik J (2001) Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 147: 1997-2005.
26. Hube B, Monod M, Schofield DA, Brown AJ, Gow NA (1994) Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 14: 87-99.
27. Kathwate GH, Karuppayil SM (2013) Antifungal properties of the anti-hypersensitive drug: Aliskiren. Arch Oral Biol 58: 1109-1115.
28. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B (1999) Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 43: 2038-2042.
29. -ΔΔCT method. Methods 25: 402-408.
30. Meiler TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Winkler R, Ton A, Jabra-Rizk AM (2009) A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS One. doi: 10. 1371/journal. pone. 0005039.
31. Naglik JR, Challacombe SJ, Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67: 400-428.
32. Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, Tappuni AR, Rodgers CA, Woodman AJ, Challacombe SJ, Schaller M, Hube B (2008) Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154: 3266-3280.
33. Naglik J, Moyes DL, Wächtler B, Hube B (2011) Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect 13: 963-976.
34. Newport G, Agabian N (1997) KEX2 influences Candida albicans proteinase secretion and hyphal formation. J Biol Chem 272: 28954-28961.
35. Ochal Z, Kamiński R (2005) Transformation of bromodichloromethyl-4-chlorophenyl sulfone into new compounds with potential pesticidal activity. Pol J Appl Chem 3: 215-255.
36. Ochal Z, Wójcicki J (2007) Transformations of chlorodibromomethyl-4-chlorophenyl sulfone into new compounds with potential pesticidal activity. Pol J Appl Chem 51: 29-41.
37. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Clinical practice guidelines for the management of Candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
38. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
39. Samaranayake DP, Hanes SD (2011) Milestones in Candida albicans gene manipulation. Fungal Genet Biol 48: 858-865.
40. Samaranayake YH, Cheung BPK, Yau JYY, Yeung SKW, Samaranayake LP (2013) Human serum promotes Candida albicans biofilm growth and virulence gene expression on silicone biomaterial. PLoS One. doi: 10. 1371/journal. pone. 0062902.
41. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62: 10-24.
42. Schild L, Heyken A, de Groot PW, Hiller E, Mock M, de Koster C, Horn U, Rupp S, Hube B (2011) Proteolytic cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and Sap10. Eukaryot Cell 10: 98-109.
43. Sherman F (2002) Getting started with yeast. Methods Enzymol 350: 3-41.
44. Shinde RB, Raut JS, Karuppayil MS (2012) Biofilm formation by Candida albicans on various prosthetic materials and its fluconazole sensitivity: a kinetic study. Mycoscience 53: 220-226.
45. Staniszewska M, Bondaryk M, Zielińska P, Urbańczyk-Lipkowska Z (2014) The in vitro effects of new D186 dendrimer on virulence factors of Candida albicans. J Antibiot. doi: 10. 1038/ja. 2014. 25.
46. Wächtler B, Wilson D, Hube B (2011) Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole. Antimicrob Agents Chemother 55: 4436-4439.
47. Walker LA, MacCallum DM, Bertram G, Gow NA, Odds FC, Brown AJ (2009) Genome-wide analysis of Candida albicans gene expression patterns during infection of the mammalian kidney. Fungal Genet Biol 46: 210-219.
48. Wang YC, Huang SH, Lan CY, Chen BS (2012) Prediction of phenotype-associated genes via a cellular network approach: a Candida albicans infection case study. PLoS One. doi: 10. 1371/journal. pone. 0035339.
49. Watamoto T, Samaranayake LP, Egusa H, Yatani H, Samaranayake YH, Seneviratne CJ (2010) Susceptibility of Candida albicans filamentation-defective mutants to clinical biocides. J Hosp Infect 74: 189-191.
50. Watts HJ, Cheah FSH, Hube B, Sanglard D, Gow NAR (1998) Altered adherence in strains of Candida albicans harbouring null mutations in secrete aspartic proteinase genes. FEMS Microbiol Lett 159: 129-135.
51. Wu T, Wright K, Hurst SF, Morrison CJ (2000) Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 44: 1200-1208.
52. Xu W, He J, He M, Han F, Chen X, Pan Z, Wang J, Tong M (2011) Synthesis and antifungal activity of novel sulfone derivatives containing 1, 3, 4-oxadiazole moieties. Molecules 16: 9129-9141.
53. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H, ESAC-3 hospital care subproject group (2012) Antifungal therapy in European hospitals: data from the ESAC-point prevalence surveys 2008 and 2009. Clin Microbiol Infect. doi: 10. 1111/j. 1469-0691. 2012. 03973. x.